EMA Withdrawn: Enviage (aliskiren) — Novartis Europharm Ltd.

View source ↗

Summary

The EMAWithdrawn notice states Enviage (aliskiren) has been withdrawn from the European market for hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Enviage (aliskiren)

Snippet

Status: Withdrawn. Therapeutic area: Hypertension. MAH: Novartis Europharm Ltd.. Decision date: 22/04/2009